Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves

Executive Summary

Novan and AC Immune ended September with the first biopharma IPOs in 40 days as the performance of newly public companies’ stocks head into an upswing.

Advertisement

Related Content

AC Immune Beefs Up Neurodegenerative Diseases Pipeline
Sienna CEO: IPO Investors Drawn By Experienced Dermatology Team
IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
Start-Up Quarterly Statistics, Q3 2016
IPO Update: Protagonist, Gemphire, Kadmon Launches Fall Flat
Scrip's Rough Guide To CRISPR Gene Editing
AC Immune Targeting $50m IPO
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
Despite Headwinds US IPOs Show Few Signs Of Slowing In Q3

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097384

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel